Search

Your search keyword '"Kakehi M"' showing total 105 results

Search Constraints

Start Over You searched for: Author "Kakehi M" Remove constraint Author: "Kakehi M"
105 results on '"Kakehi M"'

Search Results

1. Research Trends and Impact Factor on PubMed Among General Medicine Physicians in Japan: A Cross-Sectional Bibliometric Analysis

4. Write heads with pole tip consisting of high-Bs FeCoAlO films

26. Interlaboratory evaluation of LC-MS-based biomarker assays.

27. Highlights of the 15th Japan Bioanalysis Forum Symposium.

28. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.

29. Atypical Adult Still's Disease Complicated by Hemophagocytic Syndrome in an Older Patient: A Case Report.

30. Development and validation of qPCR methods for nucleic acid biomarkers as a drug development tool: points to consider.

31. Diurnal Fluctuations of Orexin-A and -B in Cynomolgus Monkey Cerebrospinal Fluid Determined by a Novel Analytical Method Using Antiadsorptive Additive Treatment Followed by Nanoflow Liquid Chromatography-High-Resolution Mass Spectrometry.

32. Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay.

33. Development and multicenter validation of an LC-MS-based bioanalytical method for antisense therapeutics.

34. Blood Neurofilament Light Chain as a Potential Biomarker for Central and Peripheral Nervous Toxicity in Rats.

36. Analytical method validation for biomarkers as a drug development tool: points to consider.

37. Genetic interactions among ADAMTS metalloproteases and basement membrane molecules in cell migration in Caenorhabditis elegans.

38. Development of a bioanalytical method for an antisense therapeutic using high-resolution mass spectrometry.

39. The 10th Japan Bioanalysis Forum Symposium conference: a report.

40. Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan.

41. Meteorological factors affecting seroconversion of Akabane disease in sentinel calves in the subtropical Okinawa Islands of Japan.

42. Characterization of Species Differences in Xenobiotic Metabolism in Non-experimental Animals.

43. The effects of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics.

44. Bioanalytical method for the simultaneous determination of D- and L-serine in human plasma by LC/MS/MS.

45. Method development for the determination of 24S-hydroxycholesterol in human plasma without derivatization by high-performance liquid chromatography with tandem mass spectrometry in atmospheric pressure chemical ionization mode.

46. Uridine Diphosphate-Glucuronosyltransferase (UGT) Xenobiotic Metabolizing Activity and Genetic Evolution in Pinniped Species.

47. Method development for the determination of D- and L-isomers of leucine in human plasma by high-performance liquid chromatography tandem mass spectrometry and its application to animal plasma samples.

48. Japanese bioanalytical method validation guideline: the world's first regulatory guideline dedicated to ligand-binding assays.

49. Identification of interspecific differences in phase II reactions: determination of metabolites in the urine of 16 mammalian species exposed to environmental pyrene.

50. Investigation of the unique metabolic fate of ethyl (6R)-6- [N- (2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) in rats and dogs using two types of 14C-labeled compounds having different labeled positions.

Catalog

Books, media, physical & digital resources